Seer, Inc. (NASDAQ:SEER - Get Free Report)'s stock price was down 2.5% during trading on Thursday . The stock traded as low as $1.99 and last traded at $1.99. 168,768 shares were traded during trading, a decline of 51% from the average session volume of 345,725 shares. The stock had previously closed at $2.04.
Seer Trading Down 0.5 %
The firm has a 50-day moving average of $1.97 and a 200 day moving average of $2.17. The stock has a market capitalization of $117.17 million, a price-to-earnings ratio of -1.51 and a beta of 1.61.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently made changes to their positions in the company. Peapod Lane Capital LLC acquired a new stake in shares of Seer during the fourth quarter valued at about $991,000. Renaissance Technologies LLC boosted its holdings in Seer by 27.0% in the fourth quarter. Renaissance Technologies LLC now owns 843,700 shares of the company's stock valued at $1,949,000 after purchasing an additional 179,568 shares during the last quarter. Two Sigma Advisers LP raised its position in shares of Seer by 24.2% in the 4th quarter. Two Sigma Advisers LP now owns 681,900 shares of the company's stock valued at $1,575,000 after purchasing an additional 132,800 shares in the last quarter. Bridgeway Capital Management LLC boosted its stake in shares of Seer by 17.6% during the 4th quarter. Bridgeway Capital Management LLC now owns 727,743 shares of the company's stock valued at $1,681,000 after buying an additional 109,000 shares during the last quarter. Finally, D. E. Shaw & Co. Inc. increased its stake in shares of Seer by 16.8% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 719,901 shares of the company's stock worth $1,663,000 after buying an additional 103,630 shares during the last quarter. 75.20% of the stock is currently owned by hedge funds and other institutional investors.
About Seer
(
Get Free Report)
Seer, Inc, a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only.
Further Reading
Before you consider Seer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Seer wasn't on the list.
While Seer currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
